End point | Hazard ratio (95%CI) | p-value |
---|---|---|
Overall survival | ||
T stage T4 vs. T1–3 | 3.914 (1.441–10.63) | 0.007 |
N stage N3 vs. 0–2 | 4.735 (1.655–13.547) | 0.004 |
Disease-free survival | ||
Gender Male vs. Female | 4.537(1.392–14.792) | 0.012 |
T stage T4 vs. T1–3 | 2.705(1.359–5.384) | 0.005 |
N stage N3 vs. 0–2 | 3.425 (1.671–7.019) | 0.001 |
Post-radiation sinusitis Yes vs. no | 3.734(1.732–8.051) | 0.001 |
Freedom from local failure | ||
T stage T4 vs. T1–3 | 2.786(1.069–7.259) | 0.036 |
Post-radiation sinusitis Yes vs. no | 8.9441(2.002–39.965) | 0.004 |
Freedom from distant failure | ||
N stage N3 vs. 0–2 | 4.982 (2.149–11.552) | < 0.001 |
Post-radiation sinusitis Yes vs. no | 2.951 (1.233–7.064) | 0.015 |